Precipio, Inc. (PRPO)
USD 5.56
(-3.81%)
USD 5.56
(-3.81%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -4.31 Million USD | 45.88% |
| 2022 | -10.64 Million USD | -38.05% |
| 2021 | -7.05 Million USD | -22.75% |
| 2020 | -8.77 Million USD | -3.56% |
| 2019 | -8.22 Million USD | -100.94% |
| 2018 | -7.96 Million USD | -152.45% |
| 2017 | -5.45 Million USD | 174.86% |
| 2016 | -1.6 Million USD | 4.03% |
| 2015 | -8.64 Million USD | 61.23% |
| 2014 | -10.5 Million USD | -35.81% |
| 2013 | -12.65 Million USD | -123.07% |
| 2012 | -5.01 Million USD | -244.0% |
| 2011 | -830 Thousand USD | 253.93% |
| 2010 | -2.27 Million USD | -71.67% |
| 2009 | -1.04 Million USD | -194.29% |
| 2008 | 600 Thousand USD | 536.88% |
| 2007 | -981 Thousand USD | 60.77% |
| 2006 | -973 Thousand USD | -144.07% |
| 2005 | 1.77 Million USD | 160.74% |
| 2004 | -6.75 Million USD | 40.98% |
| 2003 | -7.43 Million USD | 32.47% |
| 2002 | -18.28 Million USD | -82.67% |
| 2001 | -6.05 Million USD | 27.7% |
| 2000 | -7.56 Million USD | -55.3% |
| 1999 | -5.36 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -854 Thousand USD | 49.65% |
| 2024 Q1 | -1.69 Million USD | -230.36% |
| 2023 Q1 | -2.64 Million USD | -35.04% |
| 2023 FY | - USD | 45.88% |
| 2023 Q4 | -484 Thousand USD | 66.57% |
| 2023 Q3 | -1.44 Million USD | 24.23% |
| 2023 Q2 | -1.91 Million USD | 27.72% |
| 2022 Q2 | -2.05 Million USD | 55.88% |
| 2022 FY | - USD | -38.05% |
| 2022 Q3 | -2.84 Million USD | -38.57% |
| 2022 Q4 | -1.95 Million USD | 31.1% |
| 2022 Q1 | -4.64 Million USD | -121.91% |
| 2021 FY | - USD | -22.75% |
| 2021 Q2 | -909 Thousand USD | 10.09% |
| 2021 Q3 | -2.66 Million USD | -193.4% |
| 2021 Q4 | -2.09 Million USD | 21.45% |
| 2021 Q1 | -1.01 Million USD | 56.18% |
| 2020 Q2 | -1.54 Million USD | 1.28% |
| 2020 FY | - USD | -3.56% |
| 2020 Q3 | -1.24 Million USD | 18.96% |
| 2020 Q4 | -2.3 Million USD | -84.86% |
| 2020 Q1 | -1.56 Million USD | -15.9% |
| 2019 FY | - USD | -100.94% |
| 2019 Q1 | -2.13 Million USD | -180.0% |
| 2019 Q2 | -365 Thousand USD | 82.91% |
| 2019 Q3 | -2.57 Million USD | -606.58% |
| 2019 Q4 | -1.34 Million USD | 47.81% |
| 2018 Q1 | -1.91 Million USD | -136.17% |
| 2018 FY | - USD | -152.45% |
| 2018 Q4 | 2.67 Million USD | 250.42% |
| 2018 Q3 | -1.77 Million USD | 18.69% |
| 2018 Q2 | -2.18 Million USD | -14.29% |
| 2017 FY | - USD | 174.86% |
| 2017 Q1 | -1.47 Million USD | 36.33% |
| 2017 Q2 | 1.85 Million USD | 226.05% |
| 2017 Q4 | 5.28 Million USD | 1173.17% |
| 2017 Q3 | -492 Thousand USD | -126.48% |
| 2016 Q2 | -1.79 Million USD | 27.73% |
| 2016 Q4 | -2.31 Million USD | -48.97% |
| 2016 FY | - USD | 4.03% |
| 2016 Q1 | -2.48 Million USD | 72.47% |
| 2016 Q3 | -1.55 Million USD | 13.33% |
| 2015 Q3 | 4.74 Million USD | 343.46% |
| 2015 FY | - USD | 61.23% |
| 2015 Q2 | -1.94 Million USD | -0.67% |
| 2015 Q1 | -1.93 Million USD | 68.14% |
| 2015 Q4 | -9.01 Million USD | -289.95% |
| 2014 Q2 | -4.15 Million USD | -15.77% |
| 2014 FY | - USD | -35.81% |
| 2014 Q1 | -3.58 Million USD | -8.2% |
| 2014 Q4 | -6.07 Million USD | 24.7% |
| 2014 Q3 | -8.07 Million USD | -94.22% |
| 2013 FY | - USD | -123.07% |
| 2013 Q4 | -3.31 Million USD | 38.65% |
| 2013 Q2 | -2.92 Million USD | 23.51% |
| 2013 Q3 | -5.4 Million USD | -85.04% |
| 2013 Q1 | -3.82 Million USD | -49.22% |
| 2012 Q3 | -2.42 Million USD | -77.15% |
| 2012 Q4 | -2.56 Million USD | -5.48% |
| 2012 Q2 | -1.37 Million USD | 29.6% |
| 2012 Q1 | -1.94 Million USD | -395.17% |
| 2012 FY | - USD | -244.0% |
| 2011 Q4 | -393 Thousand USD | -157.21% |
| 2011 Q3 | 687 Thousand USD | -78.08% |
| 2011 Q2 | 3.13 Million USD | 1450.86% |
| 2011 Q1 | -232 Thousand USD | 86.09% |
| 2011 FY | - USD | 253.93% |
| 2010 Q3 | -538 Thousand USD | 36.33% |
| 2010 Q4 | -1.66 Million USD | -210.04% |
| 2010 Q2 | -845 Thousand USD | -125.94% |
| 2010 FY | - USD | -71.67% |
| 2010 Q1 | -374 Thousand USD | -173.33% |
| 2009 FY | - USD | -194.29% |
| 2009 Q1 | -797 Thousand USD | -142.71% |
| 2009 Q4 | 510 Thousand USD | 342.86% |
| 2009 Q3 | -210 Thousand USD | 61.61% |
| 2009 Q2 | -547 Thousand USD | 31.37% |
| 2008 Q2 | 241 Thousand USD | -17.18% |
| 2008 Q1 | 291 Thousand USD | -34.75% |
| 2008 Q3 | -384 Thousand USD | -259.34% |
| 2008 Q4 | 1.86 Million USD | 585.94% |
| 2008 FY | - USD | 536.88% |
| 2007 Q3 | 172 Thousand USD | 386.67% |
| 2007 Q1 | -992 Thousand USD | -486.98% |
| 2007 FY | - USD | 60.77% |
| 2007 Q4 | 446 Thousand USD | 159.3% |
| 2007 Q2 | -60 Thousand USD | 93.95% |
| 2006 Q4 | -169 Thousand USD | 86.39% |
| 2006 Q2 | 173 Thousand USD | 179.03% |
| 2006 Q3 | -1.24 Million USD | -817.92% |
| 2006 Q1 | 62 Thousand USD | -93.92% |
| 2006 FY | - USD | -144.07% |
| 2005 FY | - USD | 160.74% |
| 2005 Q2 | 83 Thousand USD | 149.4% |
| 2005 Q3 | 1.74 Million USD | 2003.61% |
| 2005 Q4 | 1.02 Million USD | -41.58% |
| 2005 Q1 | -168 Thousand USD | -158.46% |
| 2004 Q2 | -1.7 Million USD | 23.11% |
| 2004 Q3 | -412 Thousand USD | 75.76% |
| 2004 Q4 | -65 Thousand USD | 84.22% |
| 2004 FY | - USD | 40.98% |
| 2004 Q1 | -2.21 Million USD | -201.75% |
| 2003 Q2 | -3.14 Million USD | -20.93% |
| 2003 Q3 | -4.87 Million USD | -87.74% |
| 2003 Q4 | -2.63 Million USD | 144.62% |
| 2003 Q1 | -2.44 Million USD | -52.02% |
| 2003 FY | - USD | 32.47% |
| 2002 Q2 | -3.12 Million USD | -16.99% |
| 2002 Q4 | -4.81 Million USD | 62.72% |
| 2002 Q1 | -2.7 Million USD | -43.93% |
| 2002 FY | - USD | -82.67% |
| 2002 Q3 | -3.78 Million USD | -21.31% |
| 2001 Q4 | -1.89 Million USD | -41.56% |
| 2001 FY | - USD | 27.7% |
| 2001 Q1 | -1.53 Million USD | 33.43% |
| 2001 Q2 | -1.32 Million USD | 14.49% |
| 2001 Q3 | -1.3 Million USD | 0.98% |
| 2000 FY | - USD | -55.3% |
| 2000 Q1 | -2.52 Million USD | 0.0% |
| 2000 Q2 | -1.81 Million USD | 45.68% |
| 2000 Q3 | -1.68 Million USD | -22.42% |
| 2000 Q4 | -1.53 Million USD | -38.08% |
| 1999 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 97.979% |
| Prenetics Global Limited | -47.89 Million USD | 90.985% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -155.957% |
| CareDx, Inc | -89.65 Million USD | 95.184% |
| Exact Sciences Corporation | 41.87 Million USD | 110.311% |
| Exagen Inc. | -19.15 Million USD | 77.455% |
| Inotiv, Inc. | -26.5 Million USD | 83.709% |
| Guardant Health, Inc. | -433.3 Million USD | 99.003% |
| Biodesix, Inc. | -37.1 Million USD | 88.362% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -73.751% |
| iSpecimen Inc. | -9.1 Million USD | 52.569% |
| Natera, Inc. | -383.27 Million USD | 98.873% |
| Aspira Women's Health Inc. | -16.49 Million USD | 73.816% |
| Standard BioTools Inc. | -54.45 Million USD | 92.071% |
| 23andMe Holding Co. | -291.87 Million USD | 98.521% |
| Castle Biosciences, Inc. | -45.02 Million USD | 90.41% |
| Personalis, Inc. | -96.8 Million USD | 95.54% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 96.327% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | 54.979% |
| OpGen, Inc. | -29.51 Million USD | 85.368% |
| T2 Biosystems, Inc. | -43.87 Million USD | 90.158% |
| Myriad Genetics, Inc. | -67.8 Million USD | 93.631% |
| ICON Public Limited Company | 1.63 Billion USD | 100.265% |
| NeoGenomics, Inc. | -17.6 Million USD | 75.476% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -155.957% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 100.355% |
| RadNet, Inc. | 292.78 Million USD | 101.475% |
| MDxHealth SA | -30.46 Million USD | 85.828% |
| Psychemedics Corporation | -251 Thousand USD | -1620.319% |
| Illumina, Inc. | -608 Million USD | 99.29% |
| Check-Cap Ltd. | -17.64 Million USD | 75.534% |
| Twist Bioscience Corporation | -176.7 Million USD | 97.556% |
| DarioHealth Corp. | -53.49 Million USD | 91.928% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 90.724% |
| Sera Prognostics, Inc. | -35.28 Million USD | 87.763% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | 55.87% |
| OPKO Health, Inc. | -65.51 Million USD | 93.409% |
| Medpace Holdings, Inc. | 363.15 Million USD | 101.189% |
| Neogen Corporation | 182.59 Million USD | 102.365% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | 50.991% |
| Prenetics Global Limited | -47.89 Million USD | 90.985% |
| Mainz Biomed B.V. | -25.01 Million USD | 82.736% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | 43.402% |
| Trinity Biotech plc | -24.09 Million USD | 82.082% |
| Neuronetics, Inc. | -22.75 Million USD | 81.027% |
| Sotera Health Company | 514.14 Million USD | 100.84% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | 43.402% |